The patient, a 24-year-old man, had suffered from hunger, sweating, tachycardia and palpitation for three years. He was diagnosed as having Graves' disease (GD) and treated with methimazole (MMI)for 3 months. He noted that palpitation and perspiration seemed to particularly occur whenhe was hungry, and thus he was examinedto determine whether these symptoms were caused by hypoglycemia. As a markedly elevated immunoreactive insulin level and the presence of insulin antibody in serum were found, he was diagnosed as having insulin autoimmune syndrome (IAS). HLAtyping revealed the patient to be positive for group Bw62/Cw4/DR4, which is reportedly a specific HLAtype in MMI-treated euthyoroid GDpatients with IAS. In spite of the continuation of MMItreatment, the % binding of IRI decreased and the hypoglycemic episode disappeared. In contrast to the previously reported MMIinduced IAS in GDcases, MMIis unlikely to have exacrebated IAS in the present case, although his HLAcombination is identical to that of the previous cases. (Internal Medicine 38: 482-485, 1999) 
Introduction
The first case of spontaneous hypoglycemia without prior history of exogenous insulin administration was reported by Hirata et al in 1972 (1) . Insulin autoimmune syndrome (IAS), which consists of the combination of a high level of total serum immunoreactive insulin (IRI), the presence of insulin antibody (IA), and fasting hypoglycemia, is reportedly the third leading cause of hypoglycemia in Japan (2) . The first case of IAS associated with Graves' disease (GD) was first reported in 1974 (3). Burch et al (4) recently proposed administration of methimazole (MMI)as a risk factor in the development of IAS in GDpatients. A genetic predisposition may be important in the pathogenesis of IAS, as reflected by an apparent human lymphocyte antigen (HLA) association in the limited number of cases of IAS. According to the report by Uchigata et al, all 13 MMI-treated GDpatients later diagnosed as having IAS had HLA-Bw62/Cw4/DR4, whereas only 1 of 50 GD patients who had not developed IAS had the combination of HLABw62/Cw4/DR4 (5 (Table 2) . He often complained that cold sweating with palpitations occurred particularly whenhe was hungry and that those symptomsimproved after a meal. His plasma glucose level was disclosed to be 42 mg/dl when he felt the above symptoms, raising the possibility of hypoglycemic episode. Fasting IRI was 8 1 |i/ml, well above the upper normal limit, with %binding ofIRI as high as 70.3%. He has a positive IA titer. An abdominal computerized tomography and ultrasound examination disclosed no mass lesion in the pancreas and negative fasting tests also negated the possibility of insulinoma.
As his serum fT3 and fT4 levels were reduced with the continuation of MMI treatment, a decrease of his %binding of IRI occurred from 70.3% to 34.0% 2 months after the reduction of serum thyroid hormone levels ( Fig. 1) , which was followed by the reduction in Ab titers for Tg and TPO (Fig. 2) .
Discussion
The present case was presented with hyperthyroidism and hypoglycemic episode. Since he showed positive IA antibody together with high levels of fasting insulin and % insulin binding he was suggested as having IAS. As his IA titer decreased by the treatment with MMIdaily for 2 months, his hypoglycemic episode disappeared. It is well recognized that GDis often accompanied by autoimmunediseases such as IAS. In such a case, since the hyperthyroid state masks the hypoglycemic episode by impairing glucose tolerance, IAS-induced hypoglycemic symptoms usually occur after the thyroid function was normalized by MMI treatment. Thus far, since MMIis hypothesized to cause IAS by generating insulin antigenicity through cleavage of the disulfide bonds of the insulin molecules by its SH residue (6, 7), it is not until the introduction of treatment with MMI that GD patients develop IAS without prior evidence of insulin injection. However, methimazole, in vitro, did not have any effect on insulin structure or its immunoreactivity even at a substantially higher concentration than those obtained by the usual therapeutic doses. Therefore, it seems unlikely that SH drugs act directly on the insulin molecule in vivo. Alternatively, MMI (8) Interestingly, the present case developed a hypoglycemic is knownto propagate thyroid-specific autoaggression by continued induction of DRantigens. Since MMI is knownto rapidly reduce Graves' IgG-induced DRexpression possibly by reducing Graves' IgG (10), it is reasonable to speculate that MMItreatment decreased the IA titer by attenuating Graves' In summary,we treated a rare case whopresented a hypoglycemic episode even in the hyperthyroid state. Since his hypoglycemia was accounted for by the generation of IA, it disappeared as his %binding of IRI decreased with the normalization of thyroid function by MMItreatment. Therefore, it was unlikely that MMI exacrebated IAS in our case as all the previously reported GDcases, although his HLAcombination is Bw62/Cw4/DR4 as in the previous cases.
